FOR AUTHORS
Search
Search Results
##search.searchResults.foundPlural##
-
A rare case of keloid combined with bullous pemphigoid
1196PDF: 318HTML: 11 -
Eosinophilic annular erythema: four additional cases and a review of the literature on therapeutic options
1052PDF: 457SUPPLEMENTARY MATERIAL: 14HTML: 0 -
29 | INNOVATIVE THERAPEUTIC STRATEGIES IN GENODERMATOSIS: AN ITALIAN MULTICENTRE STUDY F. Pavan1, F. Cassalia2, S. Giordano3, A. Gelmetti4, L. Ventura5, F. Caroppo2, A. Bassi6, F. Martorana7, R. Balestri8, A. Guglielmo9, F. Ambrogio10, A. Bonvicino3, I. Neri4, P. Quaglino3, A. Belloni Fortina11 | 1Pediatrics Unit, Department of Women’s and Child’s Health (SDB), University of Padua, Italy; 2Dermatology Unit, Department of Medicine (DIMED), University of Padua, Italy; 3Department of Medical Sciences, Section of Dermatology, University of Turin, Italy; 4Dermatology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico S. Orsola-Malpighi, Italy; 5Department of Statistical Science, University of Padua, Italy; 6Unit of Dermatology, Azienda USL Toscana Nord Ovest, Lucca, Italy; 7Section of Dermatology - Department of Clinical Medicine and Surgery, University of Naples Federico II; 8Division of Dermatology, Outpatient Consultation for Rare Diseases, APSS, Trento, Italy; 9Institute of Dermatology, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), Udine, Italy; 10Section of Dermatology and Venereology, Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe-J), University of Bari “Aldo Moro”, Italy; 11Pediatric Dermatology Department of Women’s and Child’s Health (SDB), University of Padua, Italy
122PDF: 55 -
Underrepresentation of atopic dermatitis publications in pediatric journals: a bibliometric analysis
766PDF: 564SUPPLEMENTARY MATERIAL: 182HTML: 25 -
67 | LEBRIKIZUMAB FOR PAEDIATRIC PATIENTS AGED ≥6 MONTHS WITH MODERATE-TO-SEVERE AD: PHASE 3 ADORABLE-1 WEEK-16 RESULTS L. Stingeni1, L. Eichenfield2, J. Ornelas3, V. Prajapati4, C. Yang5, A. Tanaka6, S. Weidinger7, C. Flohr8, E. Swanson9, L. Martin10, S. Daveiga11, R. Gontijo Lima11, H. Elmaraghy11, E. Pierce11, P. Sen11, G. Gallo11, M. Piruzeli11, A. Larkin11, M. Grau12, Y. Mihaylov12, A. Paller13 | 1Dermatology Section, Department of Medicine and Surgery, University of Perugia, Italy; 2Departments of Dermatology and Pediatrics, University of California San Diego School of Medicine, La Jolla, California, USA; 3Department of Dermatology, Integrative Skin Science and Research, Sacramento, California, USA; 4Dermatology Research Institute, Skin Health & Wellness Centre, Probity Medical Research, and University of Calgary, Calgary, Canada; 5Chang Gung University College of Medicine, Taoyuan, Taiwan; 6Department of Dermatology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan; 7Department of Dermatology and Allergy, University Hospital Schleswig-Holstein, Kiel, Lübeck, Germany; 8Department of Dermatology and Population Health Sciences, King’s College London, UK; 9Ada West Dermatology, St Luke’s Children’s Hospital Idaho, USA; 10School of Clinical Medicine, UNSW Sydney & Dermatology Department, Sydney Children’s Hospital, Sydney, Australia; 11Eli Lilly and Company, Indianapolis, Indiana, USA; 12Almirall R&D, S.A., Barcelona, Spain; 13Dermatology and Infectious Disease, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA
166PDF: 97 -
10 | LEBRIKIZUMAB PROVIDES CLINICALLY MEANINGFUL RESPONSE IN FACE AND HANDS IN ADULTS AND ADOLESCENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS: ADHOPE 1 STUDY L. Stingeni1, C. Vestergaard2, J. Seneschal3|4, S. Weidinger5, A. Wollenberg6|7|8, A. Irvine9, H. Agell10, J. Valls Bancells10, V. Sapena10, D. Thaçi7 | 1Dermatology Section, Department of Medicine and Surgery, University of Perugia, Italy; 2Department of Dermatology and Venerology, Aarhus University Hospital, Aarhus, Denmark; 3Department of Dermatology, University of Bordeaux, Bordeaux, France; 4Department of Dermatology and Pediatric Dermatology, National Reference Center for Rare Skin Disorders, Hospital Saint-André, Bordeaux, France; 5Department of Dermatology and Allergy, University Hospital Schleswig-Holstein, Kiel, Germany; 6University Medical Center of Augsburg, Augsburg, Germany; 7Institute and Comprehensive Center for Inflammatory Medicine at the University of Lübeck, Lübeck, Germany; 8Department of Dermatology and Allergology, LMU Hospital, Munich, Germany; 9Department of Clinical Medicine, Trinity College Dublin, Dublin, Ireland; 10Almirall S.A., Barcelona, Spain
231PDF: 161 -
30 | ATOPIC DERMATITIS AND ULCERATIVE COLITIS: A CASE REPORT ON THE MANAGEMENT OF OVERLAPPING COMORBIDITIES S. Senatore1, C. Cardinali1, A. Pieraccini2, F. Taviti1 | 1SOC Dermatologia Pistoia-Prato, USL Toscana Centro, Italy; 2SOC Gastroenterologia ed Endoscopia, USL Toscana Centro, Italy
229PDF: 96 -
12 | LEBRIKIZUMAB FOR PAEDIATRIC PATIENTS AGED ≥6 MONTHS WITH MODERATE-TO-SEVERE AD: PHASE 3 ADORABLE-1 WEEK-16 RESULTS L. Stingeni1, L. Eichenfield2, J. Ornelas3, V. Prajapati4, C. Yang5, A. Tanaka6, S. Weidinger7, C. Flohr8, E. Swanson9, L. Martin10, S. Daveiga11, R. Gontijo Lima11, H. Elmaraghy11, E. Pierce11, P. Sen11, G. Gallo11, M. Piruzeli11, A. Larkin11, M. Grau12, Y. Mihaylov12, A. Paller13 | 1Dermatology Section, Department of Medicine and Surgery, University of Perugia, Italy; 2Departments of Dermatology and Pediatrics, University of California San Diego School of Medicine, La Jolla, California, US; 3Department of Dermatology, Integrative Skin Science and Research, Sacramento, California, US; 4Dermatology Research Institute, Skin Health & Wellness Centre, Probity Medical Research, and University of Calgary, Calgary, CA; 5Chang Gung University College of Medicine, Taoyuan, TW; 6Department of Dermatology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, JP; 7Department of Dermatology and Allergy, University Hospital Schleswig-Holstein, Kiel, DE; 8Department of Dermatology and Population Health Sciences, King’s College London, London, UK; 9Ada West Dermatology, St Luke's Children's Hospital, Idaho, US; 10School of Clinical Medicine, UNSW Sydney & Dermatology Department, Sydney Children’s Hospital, Sydney AU; 11Eli Lilly and Company, Indianapolis, Indiana,US; 12Almirall R&D, S.A., Barcelona, ES; 13Dermatology and Infectious Disease, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, US
244PDF: 78 -
Measuring the impact of pruritus in patients with epidermolysis bullosa: evaluation with an itch-specific instrument
1243PDF: 406APPENDIX S1: 226HTML: 20 -
Scabies mimicking relapsing atopic dermatitis
1128PDF: 730HTML: 124
1 - 25 of 25 items

